BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD)

Cell Death and Differentiation

Volumn 17, Issue 6, 2010, Pages 1011-1024

  Niikura, Y ^a   Ogi, H ^a   Kikuchi, K ^a   Kitagawa, K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Aneuploidy; BUB3; C Abl; P73; Spindle checkpoint

Indexed keywords

ABELSON KINASE; BUB1 PROTEIN; BUB3 PROTEIN; CASPASE INDEPENDENT MITOTIC DEATH PROTEIN; CELL PROTEIN; PROTEIN CIMD; PROTEIN KINASE; PROTEIN P73; PROTEIN Y99; UNCLASSIFIED DRUG;

ANEUPLOIDY; ARTICLE; CELL DEATH; CELL NUCLEUS; CELL PROTECTION; CELL SURVIVAL; CHROMOSOME; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY;

ANIMALS; CASPASES; CELL CYCLE PROTEINS; CELL DEATH; CELL NUCLEUS; CELL SURVIVAL; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; MICE; MICE, KNOCKOUT; MITOSIS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; TUMOR SUPPRESSOR PROTEINS;

EID: 77952240864     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.207     Document Type: Article

References (84)

1. Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008; 322: 703-709.
2. Hernando E. Cancer. Aneuploidy advantages? Science 2008; 322: 692-693.
3. Weaver BA, Cleveland DW. The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell 2008; 14: 431-433.
4. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006; 18: 658-667.
5. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007; 11: 25-36.
6. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-393.
7. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-651.
8. Li R, Murray AW. Feedback control of mitosis in budding yeast. Cell 1991; 66: 519-531.
9. Hoyt MA, Totis L, Roberts BT. S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell 1991; 66: 507-517.
10. Wells WA, Murray AW. Aberrantly segregating centromeres activate the spindle assembly checkpoint in budding yeast. J Cell Biol 1996; 133: 75-84.
11. Kitagawa K, Hieter P. Evolutionary conservation between budding yeast and human kinetochores. Nat Rev Mol Cell Biol 2001; 2: 678-687.
12. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5: 773-785.
13. Kops GJ. The kinetochore and spindle checkpoint in mammals. Front Biosci 2008; 13: 3606-3620.
14. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300-303.
15. Ohshima K, Haraoka S, Yoshioka S, Hamasaki M, Fujiki T, Suzumiya J et al. Mutation analysis of mitotic checkpoint genes (hBUB1 and hBUBR1) and microsatellite instability in adult T-cell leukemia/lymphoma. Cancer Lett 2000; 158: 141-150.
16. Ru HY, Chen RL, Lu WC, Chen JH. hBUB1 defects in leukemia and lymphoma cells. Oncogene 2002; 21: 4673-4679.
17. Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T et al. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene 2001; 20: 3301-3305.
18. Saeki A, Tamura S, Ito N, Kiso S, Matsuda Y, Yabuuchi I et al. Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma. Cancer 2002; 94: 2047-2054.
19. Shigeishi H, Oue N, Kuniyasu H, Wakikawa A, Yokozaki H, Ishikawa T et al. Expression of Bub1 gene correlates with tumor proliferating activity in human gastric carcinomas. Pathobiology 2001; 69: 24-29.
20. Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002; 62: 1662-1668.
21. Yoon DS, Wersto RP, Zhou W, Chrest FJ, Garrett ES, Kwon TK et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 2002; 161: 391-397.
22. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001; 409: 355-359.
23. Babu JR, Jeganathan KB, Baker DJ, Wu X, Kang-Decker N, van Deursen JM. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol 2003; 160: 341-353.
24. Dai W, Wang Q, Liu T, Swamy M, Fang Y, Xie S et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 2004; 64: 440-445.
25. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8: 413-450.
26. Blank M, Lerenthal Y, Mittelman L, Shiloh Y. Condensin I recruitment and uneven chromatin condensation precede mitotic cell death in response to DNA damage. J Cell Biol 2006; 174: 195-206.
27. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 2003; 23: 5556-5571.
28. DeLuca JG, Moree B, Hickey JM, Kilmartin JV, Salmon ED. hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol 2002; 159: 549-555.
29. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995; 1: 506-526.
30. Yang Z, Guo J, Chen Q, Ding C, Du J, Zhu X. Silencing mitosin induces misaligned chromosomes, premature chromosome decondensation before anaphase onset, and mitotic cell death. Mol Cell Biol 2005; 25: 4062-4074.
31. Kitagawa K, Niikura Y. Caspase-independent mitotic death (CIMD). Cell Cycle 2008; 7: 1001-1005.
32. Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K. BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol 2007; 178: 283-296.
33. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004; 23: 2785-2796.
34. Masud A, Mohapatra A, Lakhani SA, Ferrandino A, Hakem R, Flavell RA. Endoplasmic reticulum stress-induced death of mouse embryonic fibroblasts requires the intrinsic pathway of apoptosis. J Biol Chem 2007; 282: 14132-14139.
35. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 2004; 101: 8699-8704.
36. Taylor SS, Ha E, McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J Cell Biol 1998; 142: 1-11.
37. Tang Z, Shu H, Oncel D, Chen S, Yu H. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol Cell 2004; 16: 387-397.
38. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188: 1763-1768.
39. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 1999; 6: 389-390.
40. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62: 636-641.
41. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
42. Klanrit P, Flinterman MB, Odell EW, Melino G, Killick R, Norris JS et al. Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle 2008; 7: 205-215.
43. Kong XT, Valentine VA, Rowe ST, Valentine MB, Ragsdale ST, Jones BG et al. Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia 1999; 1: 80-89.
44. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605-615.
45. Ueda Y, Hijikata M, Takagi S, Chiba T, Shimotohno K. New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 1999; 18: 4993-4998.
46. Ueda Y, Hijikata M, Takagi S, Chiba T, Shimotohno K. Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochem J 2001; 356 (Part 3): 859-866.
47. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113 (Part 10): 1661-1670.
48. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18: 244-252.
49. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817.
50. Ben-Yehoyada M, Ben-Dor I, Shaul Y. c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J Biol Chem 2003; 278: 34475-34482.
51. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13: 962-972.
52. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-2691.
53. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404: 99-103.
54. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363-373.
55. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
56. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002; 160: 631-639.
57. Vernole P, Neale MH, Barcaroli D, Munarriz E, Knight RA, Tomasini R et al. TAp73alpha binds the kinetochore proteins Bub1 and Bub3 resulting in polyploidy. Cell Cycle 2009; 8: 421-429.
58. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A et al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA 2009; 106: 797-802.
59. Grabsch HI, Askham JM, Morrison EE, Pomjanski N, Lickvers K, Parsons WJ et al. Expression of BUB1 protein in gastric cancer correlates with the histological subtype, but not with DNA ploidy or microsatellite instability. J Pathol 2004; 202: 208-214.
60. Shin HJ, Baek KH, Jeon AH, Park MT, Lee SJ, Kang CM et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2003; 4: 483-497.
61. Sze KM, Ching YP, Jin DY, Ng IO. Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells. J Biomed Sci 2004; 11: 920-927.
62. Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000; 21: 2293-2297.
63. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, van Deursen JM. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J Cell Biol 2007; 179: 255-267.
64. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci USA 2004; 101: 17456-17461.
65. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004; 22: 247-306.
66. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
67. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007; 117: 2033-2035.
68. Pendergast AM, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 1993; 13: 1728-1736.
69. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
70. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829-3840.
71. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
72. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995; 376: 785-788.
73. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 1997; 94: 1437-1440.
74. Wang X, Babu JR, Harden JM, Jablonski SA, Gazi MH, Lingle WL et al. The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins. J Biol Chem 2001; 276: 26559-26567.
75. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
76. Reilly PT, Wysocka J, Herr W. Inactivation of the retinoblastoma protein family can bypass the HCF-1 defect in tsBN67 cell proliferation and cytokinesis. Mol Cell Biol 2002; 22: 6767-6778.
77. Kranc KR, Bamforth SD, Braganca J, Norbury C, van Lohuizen M, Bhattacharya S. Transcriptional coactivator Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation via Ink4a/ARF. Mol Cell Biol 2003; 23: 7658-7666.
78. Kitagawa K, Skowyra D, Elledge SJ, Harper JW, Hieter P. SGT1 encodes an essential component of the yeast kinetochore assembly pathway and a novel subunit of the SCF ubiquitin ligase complex. Mol Cell 1999; 4: 21-33.
79. Lamb JR, Tugendreich S, Hieter P. Tetratrico peptide repeat interactions: to TPR or not to TPR? Trends Biochem Sci 1995; 20: 257-259.
80. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002; 10: 1307-1318.
81. Tugendreich S, Tomkiel J, Earnshaw W, Hieter P. CDC27Hs colocalizes with CDC16Hs to the centrosome and mitotic spindle and is essential for the metaphase to anaphase transition. Cell 1995; 81: 261-268.
82. Yoda K, Nakamura T, Masumoto H, Suzuki N, Kitagawa K, Nakano M et al. Centromere protein B of African green monkey cells: gene structure, cellular expression, and centromeric localization. Mol Cell Biol 1996; 16: 5169-5177.
83. Niikura Y, Ohta S, Vandenbeldt KJ, Abdulle R, McEwen BF, Kitagawa K. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation. Oncogene 2006; 25: 4133-4146.
84. Bansal PK, Mishra A, High AA, Abdulle R, Kitagawa K. Sgt1 dimerization is negatively regulated by protein kinase CK2-mediated phosphorylation at Ser361. J Biol Chem 2009; 284: 18692-18698.